A Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in the Cerebrospinal Fluid (CSF) of Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2010
At a glance
- Drugs Nelonicline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 02 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2009 Planned number of patients changed from 8 to 10 as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record